Three-drug combo targets immune suppression to overcome melanoma resistance

For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...
CURE

FDA Fully Approves Braftovi Combo for BRAF V600E Metastatic Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-gra…

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with ...
Technology Networks

Three Drug Combination Enhances Immune Response to Melanoma

Researchers found that combining trametinib, rigosertib, and a CD40 agonist blocked immune-suppressive B cells and restored ...
Yahoo

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...
Healio

Encorafenib combination secures FDA approval for metastatic colorectal cancer

The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...
GlobalData on MSN

Second Pfizer Braftovi regimen shows benefit in mCRC

This recent readout follows successful data from another combination including Braftovi in mCRC.
ascopubs.org

Using Artificial Intelligence to Support Informed Decision-Making on BRAF Mutation Testing

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
ascopubs.org

Analysis of BRAF mutations in circulating tumor cells selected by size from patients with melanoma and comparision to the primary tumor.

Gene expression panel (TheraPrint) analyzed as predictors of response to neoadjuvant chemotherapy (NCT) in patients (pts) with stage II-III and inflammatory breast cancer (BC). This is an ASCO Meeting ...